SCHEMBL10019243

SCHEMBL10019243

CC(=O)N(CCCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)c1cccc(C#N)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.37
KCNA5 P22460 1/20 0.37
BACE1 P56817 1/20 0.35
VNN1 O95497 1/20 0.34
KCNA3 P22001 1/20 0.34
ACHE P22303 2/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
GRM5 P41594 2/20 0.33
SLC16A3 O15427 1/20 0.33
SLC16A1 P53985 1/20 0.33
MCTS1 Q9ULC4 1/20 0.33
SMYD2 Q9NRG4 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
MAPK1 P28482 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10019242 0.76 KCNN4 (0.41) KCNN4KCNA5KCNA3KDM4EGABRA1
SCHEMBL10019239 0.75 KCNN4 (0.41) KCNN4KCNA5KDM4EGABRA1GABRG2
SCHEMBL10019241 0.73 ICMT (0.41) KCNA5BACE1ACHEMAPK1
SCHEMBL30945338 0.72 HTR7 (0.43) MTNR1AMTNR1B
SCHEMBL20954508 0.72 HTR7 (0.43) MTNR1AMTNR1B
SCHEMBL16560398 0.71 LTA4H (0.43) SMYD2KDM4EMEN1KMT2A
SCHEMBL17755998 0.70 SMYD2 (0.42) SMYD2PPARA
SCHEMBL16560397 0.69 LTA4H (0.52) MEN1KMT2A
SCHEMBL5036230 0.69 KDM4E (0.51) KCNN4KCNA5GRM5KDM4EGABRA1
SCHEMBL25331014 0.69 TDP1 (0.37) SMYD2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101619-B2 Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition SOLVAY PHARMACEUTICALS B.V. (NL) 2012-01-24 US disclosed